Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Colorectal Neoplasms 86Colonic Neoplasms 32Rectal Neoplasms 31Neoplasms 24Pancreatic Neoplasms 22Stomach Neoplasms 20Neoplasm Metastasis 20Esophageal Neoplasms 20Neuroblastoma 12Glioma 11Sarcoma 9Glioblastoma 9Small Cell Lung Carcinoma 8Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Adenocarcinoma Of Esophagus 8Rhabdomyosarcoma 7Lung Neoplasms 7Sarcoma, Ewing 6Gliosarcoma 6Esophageal Squamous Cell Carcinoma 6Medulloblastoma 5Central Nervous System Neoplasms 5Breast Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Digestive System Diseases 4Adenocarcinoma 4

Interventions

Everolimus 16Octreotide 6pembrolizumab 5lanreotide 5Sunitinib 5Magnetic Resonance Spectroscopy 5gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3lenvatinib 3arginyllysine 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2pasireotide 2lutetium Lu 177 dotatate 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroendocrine Tumors × Irinotecan × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡